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TO THE EDITOR
The identification of molecules that are
involved in maintaining melanoma
cell survival is required for a better
understanding of melanoma biology
(Smalley, 2010) and identification
of potential markers for prediction of
tumor recurrence and response to
therapy (Gould Rothberg and Rimm,
2010). Recent evidence assigns to
BAG3 protein, a member of the family
of heat-shock protein (HSP) 70 co-
chaperones that share BAG domain, a
prosurvival role in some tumor types
(Rosati et al., 2007). In an in vivomodel
of human melanoma xenograft in nude
mice, we recently showed that BAG3
interferes with the HSP70-mediated
delivery of the kappa B kinase (IKK)-g
subunit of IKK complex to proteasome,
thereby sustaining NF-kB activation
and inhibiting cell apoptosis; bag3
silencing resulted in a significant re-
duction in tumor growth and prolonged
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Figure 1. Analysis of BAG3 expression in human melanomas. (a) Two tissue microarrays purchased from US Biomax (Rockville, MD) were analyzed by
immunohistochemistry (IHC) using the anti-BAG3 mAbs AC-1 (ENZO Life Sciences, Lausen, Switzerland) or AC-2 (produced in our laboratories). IHC protocol
included deparaffination in xylene, rehydration through descending degrees of alcohol up to water, nonenzymatic antigen retrieval in citrate buffer, pH 6.0, for
30minutes at 95 1C, and endogenous phosphatase quenching with a 20% acetic acid solution for 20minutes at 4 1C. After rinsing with phosphate-buffered saline
(PBS), the samples were blocked with 5% normal horse serum in 0.1% PBS/BSA. To detect BAG3, samples were incubated for 1 hour at room temperature with
mAb in saturating conditions. After washing thoroughly with PBS, sections were incubated with the MACH 2 Mouse
AP-Polymer Detection system, according to the manufacturer’s instructions (Biocare Medical, Concord, CA), and complexed and developed with Vulcan fast red
(Biocarta US, San Diego, CA). Finally, the sections were counterstained with hematoxylin and dehydrated and mounted with Permount (Fisher, Illkirch, France).
BAG3 in normal tissues is not detectable. For BAG3-positive melanomas, we showed a high BAG3 staining in cutaneous melanoma cells and a sample of eye
melanoma in which BAG3 is highly expressed in spindle cells of choroid melanoma mixed type. Bar¼50 mm. (b) BRAF mutation was detected as described
previously (Casula et al., 2004). BAG3 expression was assessed as described above. (c) BAG3 low positivity and high positivity were assessed as described in the
text. Graph depicts percentage distribution of BAG3 positivity in two different groups. Statistical significance was assessed with w2-test using SPSS (Statistical
Package for the Social Sciences, release 13) software (SPSS, Chicago, IL). mut, mutation; WT, wild type.
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animal survival (Ammirante et al.,
2010). Those results prompted us to
investigate BAG3 expression in primary
melanomas, in order to verify whether
this protein contributes to melanoma
biology and might constitute a possible
prognostic marker and/or a potential
target for therapy.
We examined BAG3 levels in
human melanomas from skin or eye,
compared with the corresponding nor-
mal tissues, by immunohistochemistry.
We analyzed 16 samples of normal skin
and 11 samples of normal eye tissues.
In parallel, we analyzed 62 samples of
skin melanomas and 13 samples of
eye melanomas (10 from ciliary body
and 3 from choroid lesions). To evalu-
ate BAG3 positivity in cancer tissue
samples, we first chose for each sample
at least five hotspots by observation
with a 100 magnification. At least 10
nonoverlapping fields were analyzed at
 400 magnification for each hotspot
and results were expressed as per-
centage of positive cancer cells. The
median percentage of BAG3 positivity
calculated as described was 10%, and
this value was used as cutoff. BAG3 low
positivity was assigned to samples with
p10% of BAG3-positive cells, whereas
samples with 410% of BAG3-positive
cells were grouped as BAG3 high
positive (Figure 1a).
Although all normal tissue samples
were negative for BAG3 expression,
62.7% of melanoma specimens were
positive (Table 1). Staining was ob-
served predominantly in the cytoplasm
of tumor cells (Figure 1a). No correla-
tion between BRAF mutation (V600E is
found in 60% of these tumors) and
BAG3 expression level was found
(Figure 1b). Interestingly, analysis of
14 samples of benign nevi show that
these lesions are in vast majority
negative for BAG3 expression; indeed,
only two samples showed a low BAG3
positivity, and none were high positive.
We observed a significantly different
distribution of BAG3 positivity between
skin and eye melanomas (w2-test
P¼0.0047): indeed, BAG3-negative
samples included 29% and 77% of
skin or eye melanomas, respectively
(Table 1). This distribution likely
reflects differences in the biology of
the two melanoma types. It is interest-
ing to note that all eye melanomas
analyzed were from ciliary body or
choroid lesions. These lesions, different
from conjunctival and uveal tumors, are
not exposed to sunlight radiation, and
in fact UV exposure is not considered a
major factor in the etiology of ciliary
body and choroidal melanomas
(Hu, 2005). We might therefore spec-
ulate that exposure to sunlight could
contribute to BAG3 expression in
melanomas; indeed, it is well known
that stressful agents, including UV
exposure, can induce bag3 gene ex-
pression (Rosati et al., 2007).
We also analyzed BAG3 expression
in melanoma metastasis and compared
expression of BAG3 with that in pri-
mary tumors. We analyzed 55 lympho-
node metastases and 7 metastases to
distant organs. Although BAG3-nega-
tive samples included 37.4% of primary
tumors, only 18.2% of lymphonode
metastases, and none of the metastases
to distant organs, were negative. More-
over, metastases showed higher levels
of BAG3 as high positive samples
increased from 32% observed in pri-
mary tumors, to 45.5% in metastases to
lymphonodes, and to 85.7% in the
subset from distant metastasis (w2-test
P¼0.014; Figure 1c). This observation
is in agreement with previous data that
correlate BAG3 protein with cell motil-
ity and metastasization (Iwasaki et al.,
2007; Kassis et al., 2009).
In conclusion, our results clearly
show that BAG3 is expressed in a
proportion of melanomas and in the
majority of metastases, suggesting a
potential role for this protein in tumor
development; this is in accordance with
our previously published data demon-
strating the contribution of the protein to
melanoma cell survival in experimental
models (Ammirante et al., 2010). We
believe that future extensive analyses of
BAG3 expression in melanoma patients
will uncover correlations with specific
features of the tumor, opening the
possibility of using BAG3 as a prognos-
tic marker. Moreover, investigating a
potential correlation between BAG3
expression and response to therapeutic
agents might result in the ability
to predict treatment outcome. Finally,
in the near future, BAG3-positive
tumors could constitute candidates for
BAG3-based therapeutic approaches.
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Table 1. BAG3 expression in normal versus melanoma affected tissues
Tissue type
No. of
samples M F
Age
(years±SE)
BAG3 negative,
n (%)
BAG3 low
positive, n (%)
BAG3 high
positive, n (%)
Normal skin 16 7 9 38.2±2.8 16 (100) 0 (0) 0 (0)
Normal eye 11 11 0 35.3±0.87 11 (100) 0 (0) 0 (0)
Benign nevi 14 7 7 42.2±3.3 12 (85.7) 2 (14.3) 0 (0)
Skin melanomas 62 41 21 57.4±1.7 18 (29.0) 21 (33.8) 23 (37.2)1
Eye melanomas 13 6 7 51.8±3.3 10 (77.0) 2 (15.3) 1 (7.7)1
Melanomas in other sites 52 20 32 54.3±2.1 17 (32.7) 15 (28.8) 20 (38.5)
Abbreviations: F, female; M, male.
1w2 test: BAG3 range of positivity in skin melanomas versus eye melanomas: P=0.0047.
Bold values were used for the w2-test.
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Merkel Cell Carcinoma and Merkel Cell Polyomavirus:
Evidence for Hit-and-Run Oncogenesis
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TO THE EDITOR
In the majority of cases, Merkel cell
carcinoma (MCC) harbors Merkel cell
polyomavirus (MCV) DNA, which—at
least in the tested cases—is clonally
integrated at random sites of the host
genome and carries characteristic mu-
tations (Feng et al., 2008; Shuda et al.,
2008; Sastre-Garau et al., 2009). The
latter notion together with our recent
reports demonstrating that the expres-
sion of the MCV-derived T antigens
(TAs) is essential for growth of MCC cell
lines in vitro, and in vivo has estab-
lished MCV as a causative factor in the
oncogenesis of MCC (Houben et al.,
2010, 2011). The immunological char-
acteristics of MCC as discussed in
recent reports corroborates with this
hypothesis (Paulson et al., 2011; Touze
et al., 2011). For example, Touze et al.
(2011) demonstrated that high titers of
antibodies against the viral capsid
protein VP1 are more frequently de-
tected in MCC patients—although VP1
seems not to be expressed in the
tumors—than in a control cohort further
supporting MCV infection as a causa-
tive factor in most MCC cases. More-
over, Touze et al. (2011) confirm
several previous reports that in a sub-
stantial fraction of the MCV-positive
MCCs the virus is present with less than
one copy per cell. For these tumors a
role of MCV in their etiology is unclear.
In this regard, published data on the
impact of MCV presence or viral load
on the clinical characteristics of MCC is
conflicting. In two recent reports, a
worse prognosis for patients with MCV-
negative tumors or tumors with low
viral copy per cell numbers and lack of
large T-antigen (LTA) expression have
been reported (Sihto et al., 2009; Bhatia
et al., 2010). In others, as well as in our
own series, no statistical significant
survival differences between patients
with MCV-positive or -negative tumors
were evident (Handschel et al., 2010;
Schrama et al., 2011). In their recent
publication, Touze et al. (2011) re-
ported a better progression-free survival
for patients with high MCV VP1 anti-
body titers. Thus, based on their own
findings and the reports in the literature,
they suggest a model with two sub-
groups of MCC: one less aggressive
with clear MCV etiology, as demon-
strated by high viral load, LTA expres-
sion, and high titers of MCV antibodies;
and a second more aggressive type of
MCC with a different etiology, as
indicated by low viral load, lack of
LTA expression, and MCV antibody
titers similar to those observed in the
general population. However, although
high MCV antibody titers (410,000)
are observed in only 7.3% of the
controls, 61.5%, 65%, and 61.1% of
the MCC patients with a virus copy per
cell of o1, 1–9, and 49, respectively,
demonstrated such a high anti-VP1
antibody titers (Touze et al., 2011)
arguing against a correlation of viral
load and anti-VP1 antibody titer. In
contrast, however, VP1 antibody titers
in non-MCC patients seem to be correl-
ative to viral presence in the skin (Faust
et al., 2011). Consequently, when high-
er MCV antibodies levels in MCC
patients are regarded as an indication
for MCV etiology, these data would
support the idea that MCV has also
been a causal factor for many MCCs
even if the MCV genome is not detected
in every cell at the time of analysis. It
seems conceivable that viral infection
initially induces transformation, but
that some transformed cells may be-
come independent of MCV. Indeed,
adenovirus transformed hamster cells
can retain their oncogenic phenotype
even though the previously integrated
Abbreviations: LTA, large T antigen; MCC, Merkel cell carcinoma; MCV, Merkel cell polyomavirus;
shRNA, small hairpin RNA; TA, T antigen
254 Journal of Investigative Dermatology (2012), Volume 132
R Houben et al.
TA-Independent MCV-Positive MCC Cell Line
